AKT1 and cancer: The occurrence of TERTp mutations is significantly accompanied by driver mutations in the PI3K/AKT pathway, in line with the higher prevalence of TERTp mutations in aggressive cancers, because constitutive activation of the PI3K/AKT pathway is distinguishable in less differentiated tumors (5, 9, 10).